Melanoma
Conditions
Keywords
Melanoma stage IIIB or C with BRAF mutation, Recurrent regional lymphadenopathy not suitable for surgery, Eligible for neoadjuvant vemurafenib and cobimetinib
Brief summary
This study will evaluate the clinical and pathological response to vemurafenib and cobimetinib in the neoadjuvant treatment of patients with histologically confirmed, BRAF V600 mutation-positive Stage IIIB and C melanoma. 20 patients will be treated with vemurafenib and cobimetinib for 2 months. Then they will be assessed for surgery. Patients will undergo surgery and subsequently resume taking vemurafenib and cobimetinib after recovery from surgery. Patients will undergo radiation therapy if appropriate then continue vemurafenib and cobimetinib. The maximum treatment period is 12 months. After 12 months of treatment, patients will be followed for disease recurrence and survival during for a total of 5 years.
Detailed description
At Screening: Assessments will include CT or MRI of the brain, CT of chest, abdomen and pelvis, dermatology assessment, head and neck exam, pelvic and anal exam, ophthalmology exam, electrocardiogram (ECG), echocardiogram (ECHO) or multigated acquisition (MUGA) scan, a history and physical exam. A core biopsy will be performed within 14 days of study entry. During Treatment: The maximum treatment period is 12 months. Patients will be assessed monthly while on treatment. Assessments performed will include vital signs assessment and physical exam, dermatology exam, ophthalmology exam, echocardiogram (ECHO) or multigated acquisition (MUGA) scan, electrocardiogram (ECG), safety blood tests, pelvic and anal exam. Follow-up after treatment: Patients will be followed for 5 years. Radiology exams will be done to assess for disease. Other assessments performed include vital signs assessment and physical exam, dermatology exam, include echogram (ECHO) or multigated acquisition (MUGA) scans.
Interventions
DRUGVemurafenib
Drug
DRUGCobimetinib
Drug
Sponsors
Sunnybrook Health Sciences Centre
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Naïve to treatment for locally advanced unresectable disease (Stage IIIB and C). Prior adjuvant therapy (including immunotherapy, e.g., ipilimumab) is allowed if prior to nodal recurrence and ≥ 3 months have elapsed from the last day of adjuvant therapy to start of study treatment. 2. Biopsy proven unresected melanoma patients with palpable regional lymph node metastases, presenting with AJCC stage IIIB-C or with recurrent regional lymphadenopathy that are not suitable or not preferred for surgical intervention. 3. BRAF V600 mutation positive. 4. Eastern Cooperative Oncology Group performance status of 0 or 1. 5. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 6. Adequate hematologic, renal and liver function within 7 days prior to the first dose of vemurafenib and cobimetinib. 7. Agree to always use an effective form(s) of contraception beginning from the informed consent signature date until at least 6 months after completion of study therapy. 8. Negative serum pregnancy test within 14 days prior to start of treatment in women of childbearing potential only. 9. Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
Exclusion criteria
1. Cannot have received any prior therapy for the current recurrence or nodal disease. Previous adjuvant immunotherapy is allowed if prior to nodal recurrence and ≥ 3 months have elapsed from the last day of adjuvant therapy to start of study treatment. 2. History of prior RAF or MEK pathway inhibitor treatment. 3. Active malignancy (other than BRAF-mutated melanoma) or a previous malignancy within the past 3 years are excluded; except for patients with resected melanoma, resected basal cell carcinoma (BCC), resected cutaneous squamous cell carcinoma (SCC), resected melanoma in situ, resected carcinoma in-situ of the cervix, and resected carcinoma in-situ of the breast. 4. Evidence of distant metastatic disease. 5. History of clinically significant liver disease (including cirrhosis), current alcohol abuse, or known infection with Human Immunodeficiency Virus (HIV), hepatitis B virus, or hepatitis C virus. 6. Active infection or chronic infection requiring chronic suppressive antibiotics. 7. Pregnant or breastfeeding at the time of enrollment. 8. Active autoimmune disease (e.g., systemic lupus erythematosus, autoimmune vasculitis, inflammatory bowel disease \[Crohn's disease and ulcerative colitis\]). 9. Acromegaly 10. History of malabsorption or other clinically significant metabolic dysfunction. 11. Any other serious concomitant medical condition that would compromise safety or compromise the ability to participate in the study. 12. Requires a concomitant medication or dietary supplement that is prohibited during the study. 13. Unwillingness or inability to comply with study and follow-up procedures. 14. Current, recent (within 28 days of enrolment) or planned use of any investigational product outside of this study. 15. The following foods or supplements are prohibited at least 7 days prior to initiation of and during study treatment: 1. St. John's wort or hyperforin 2. Grapefruit juice 16. History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment / central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration. 17. Currently are known to have the following conditions: 1. Uncontrolled glaucoma with intra-ocular pressures with \> 21 mmHg 2. Retinal venous occlusion (RVO) 3. Hypertensive retinopathy 18. Clinically significant cardiac dysfunction, including the following: 1. Current unstable angina 2. Current symptomatic congestive heart failure of New York Heart Association class 2 or higher 3. History of congenital long QT syndrome or QTcF \> 450 msec at baseline or uncorrectable abnormalities in serum electrolytes (sodium, potassium, calcium, magnesium, phosphorus). 4. Current uncontrolled hypertension ≥Grade 2 (patients with a history of hypertension controlled with anti-hypertensives to ≤ Grade 1 are eligible). 5. Left ventricular ejection fraction (LVEF) below institutional lower limit of normal (LLN) or below 50%, whichever is lower. 17\. Palliative radiotherapy or major surgery within 14 days prior to first dose of study treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The feasibility of treating patients with unresectable melanoma and palpable lymph node metastases that harbor the BRAF mutation with neoadjuvant vemurafenib. | 24 months |
Secondary
| Measure | Time frame |
|---|---|
| Local-regional recurrence rates after treatment with neo-adjuvant vemurafenib. | 5 years |
| Time to distant metastases and Distant Metastatic Free Survival (DMFS). | 5 years |
| Resectability rates post vemurafenib therapy | 5 years |
| Immunohistochemical correlates of tumor response. | 5 years |
| Safety and tolerability of vemurafenib in the neoadjuvant setting | 5 years |
| Disease Free Survival (DFS) and Overall Survival (OS). | 5 years |
Countries
Canada
Outcome results
None listed